5-[(2-Methylpropan-2-yl)oxy]-1,3-oxazole

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-[(2-Methylpropan-2-yl)oxy]-1,3-oxazole
• 英文别名: 5-[(2-methylpropan-2-yl)oxy]-1,3-oxazole
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: ZYTZANOAQGNFQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel Dosage Form
  申请人：NeuroVive Pharmaceutical AB

  公开号：US20140234414A1

  公开（公告）日：2014-08-21

  There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.

  提供了一种用于口服的药物剂型，包括桑格利非林作为活性成分，其中桑格利非林活性成分在口服后受到胃酸降解的保护。
• N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
  申请人：C4 Therapeutics, Inc.

  公开号：US20200140456A1

  公开（公告）日：2020-05-07

  This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.
• US9504728B2
  申请人：——

  公开号：US9504728B2

  公开（公告）日：2016-11-29